Clinical trial
Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas
NCT00210366 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas
- Lead sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 30, 2004
- Completion date
- Not reported
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.